Photodynamic therapy

Journal of the National Cancer Institute

Volumn 90, Issue 12, 1998, Pages 889-905

  Dougherty, Thomas J ^a   Gomer, Charles J ^b,c   Henderson, Barbara W ^a   Jori, Giulio ^d   Kessel, David ^e   Korbelik, Mladen ^f   Moan, Johan ^g   Peng, Qian ^g  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF PADOVA   (Italy)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; BENZODIAZEPINE RECEPTOR; BENZOPORPHYRIN DERIVATIVE; ETIOPURPURIN; HEMATOPORPHYRIN DERIVATIVE; HEME; LUTETIUM; PHOTOFRIN; PHOTOSENSITIZING AGENT; PRODRUG; PROTOPORPHYRIN; PURPURIN; TALAPORFIN; TEMOPORFIN;

APOPTOSIS; CLINICAL PROTOCOL; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DRUG APPROVAL; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG TARGETING; DRUG UPTAKE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTHERMIC THERAPY; LUNG CANCER; NONHUMAN; PHOTOACTIVATION; PHOTOCHEMISTRY; PHOTODYNAMIC THERAPY; REVIEW; UROGENITAL TRACT CANCER;

EID: 0032540701     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.12.889     Document Type: Review

References (221)

1. von Tappeiner H, Jodlbauer A. Über die Wirkung der photodynamischen (fluorescierenden) Stoffe auf Protozoen und Enzyme. Deutsches Arch Klin Med 1904;39:427-87.
2. Blum HF. Photodynamic action and diseases caused by light. New York: Reinhold, 1941. Reprinted. New York: Hafner. 1964.
3. Moan J, Berg K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol 1991;53: 549-53.
4. Dougherty TJ, Henderson B. Historical perspective: Schwartz S, Winkelman JW, Lipson RL. In: Henderson BW, Dougherty TJ, editors. Photodynamic therapy. New York: Marcel Dekker Inc., 1992:1-15.
5. Moan J. Porphyrin photosensitization and phototherapy. Photochem Photobiol 1986;43:681-90.
6. Dougherty TJ. A brief history of clinical photodynamic therapy development at Roswell Park Cancer Institute. J Clin Laser Med 1996;14:219-21.
7. Gomer CJ. Preclinical examination of first and second generation photosensitizers used in photodynamic therapy. Photochem Photobiol 1991;54: 1093-107.
8. Pass HI. Photodynamic therapy in oncology: mechanisms and clinical use. J Natl Cancer Inst 1993;85:443-56.
9. Peng Q, Moan J, Nesland JM. Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy. Ultrastruct Pathol 1996;20:109-29.
10. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol 1992;55:145-57.
11. Salet C. Hematoporphyrin and hematoporphyrin-derivative photosensitization of mitochondria. Biochimie 1986;68:865-8.
12. Murant RS, Gibson SL, Hilf R. Photosensitizing effects of Photofrin II on the site-selected mitochondrial enzymes adenylate kinase and monoamine oxidase. Cancer Res 1987;47:4323-8.
13. Sharkey SM, Wilson BC, Moorehead R, Singh G. Mitochondrial alterations in photodynamic therapy-resistant cells. Cancer Res 1993;53: 4994-9.
14. Henderson BW, Bellnier DA, Greco WR, Sharma A, Pandey RK, Vaughan LA, et al. An in vivo quantitative structure-activity relationship for a congeneric series of pyropheophorbide derivatives as photosensitizers for photodynamic therapy. Cancer Res 1997;57:4000-7.
15. Tsuchida T, Zheng G, Pandey RK, Potter WR, Bellnier DA, Henderson BW, et al. Correlation between site II-specific human serum albumin (HSA) binding affinity and murine in vivo photosensitizing efficacy of some Photofrin components. Photochem Photobiol 1997;66:224-8.
16. Kessel D, Woodburn K, Gomer CJ, Jagerovic N, Smith KM. Photosensitization with derivatives of chlorin p6. J Photochem Photobiol B 1995; 28:13-8.
17. Kessel D, Woodburn K, Henderson BW, Chang CK. Sites of photodamage in vivo and in vitro by a cationic porphyrin. Photochem Photobiol 1995;62:875-81.
18. Kessel D, Luo Y. Mitochondrial photodamage and PDT-induced apoptosis. J Photochem Photobiol B 1998;42:89-95.
19. Berg K, Moan J. Lysosomes and microtubules as targets for photochemotherapy of cancer. Photochem Photobiol 1997;65:403-9.
20. Berg K, Steen HB, Winkelman JW, Moan J. Synergistic effects of photoactivated tetra(4-sulfonatophenyl)porphine and nocodazole on microtubule assembly, accumulation of cells in mitosis and cell survival. J Photochem Photobiol B 1992;13:59-70.
21. Moan J, Peng Q, Evensen JF, Berg K, Western A, Rimington C. Photosensitizing efficiencies, tumor-and cellular uptake of different photosensitizing drugs relevant for photodynamic therapy of cancer. Photochem Photobiol 1987;46:713-21.
22. Moan J, Pettersen EO, Christensen T. The mechanism of photodynamic inactivation of human cells in vitro in the presence of haematoporphyrin. Br J Cancer 1979;39:398-407.
23. Volden G, Christensen T, Moan J. Photodynamic membrane damage of hematoporphyrin derivative-treated NHIK 3025 cells in vitro. Photobiochem Photobiophys 1981;3:105-11.
24. Moan J, McGhie J, Jacobsen PB. Photodynamic effects on cells in vitro exposed to hematoporphyrin derivative and light. Photochem Photobiol 1983;37:599-604.
25. Specht KG, Rodgers MA. Depolarization of mouse myeloma cell membranes during photodynamic action. Photochem Photobiol 1990;51: 319-24.
26. Moan J, Christensen T. Cellular uptake and photodynamic effect of hematoporphyrin. Photobiochem Photobiophys 1981;2:291-9.
27. Christensen T, Volden G, Moan J, Sandquist T. Release of lysosomal enzymes and lactate dehydrogenase due to hematoporphyrin derivative and light irradiation of NHIK 3025 cells in vitro. Ann Clin Res 1982;14: 46-52.
28. 2+-ATPaSe in R3230AC rat mammary adenocarcinomas. Cancer Res 1988;48:3360-6.
29. 2+ influx induced by photodynamic action in human cerebral glioma (U-87 MG) cells: possible involvement of a calcium channel. Photochem Photobiol 1994;60:244-8.
30. Davies CL, Western A, Lindmo T, Moan J. Changes in antigens expression on human FME melanoma cells after exposure to photoactivated hematoporphyrin derivatives. Cancer Res 1986;46:6068-72.
31. Thomas JP, Girotti AW. Role of lipid peroxidation in hematoporphyrin derivative-sensitized photokilling of tumor cells: protective effects of glutathione peroxidase. Cancer Res 1989;49:1682-6.
32. Reyftman JB, Santus R, Morliere P, Kohan E. Fluorescent products formed by reaction of amino acids and spermidine with lipid peroxides produced by porphyrin photosensitization in ionic micelles. Photobiochem Photobiophys 1986;11:197-208.
33. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26:239-57.
34. Agarwal ML, Clay ME, Harvey EJ, Evans HH, Antunez AR, Oleinick NL. Photodynamic therapy induces rapid cell death by apoptosis in L5178Y mouse lymphoma cells. Cancer Res 1991;51:5993-6.
35. He XY, Sikes RA, Thomsen S, Chung LW, Jacques SL. Photodynamic therapy with photofrin II induces programmed cell death in carcinoma cell lines. Photochem Photobiol 1994;59:468-73.
36. Zaidi SI, Oleinick NL, Zaim MT, Mukhtar H. Apoptosis during photodynamic therapy-induced ablation of RIF-1 tumors in C3H mice: electron microscopic, histopathologic and biochemical evidence. Photochem Photobiol 1993;58:771-6.
37. Webber J, Luo Y, Crilly R, Fromm D, Kessel D. An apoptotic response to photodynamic therapy with endogenous protoporphyrin in vivo. J Photochem Photobiol B 1996;35:209-11.
38. Vaux DL, Strasser A. The molecular biology of apoptosis Proc Natl Acad Sci U S A 1996;93:2239-44.
39. Samali A, Gorman AM, Cotter TG. Apoptosis - the story so far. . . . Experientia 1996;52:933-41.
40. Hickman JA, Potten CS, Merritt AJ, Fisher TC. Apoptosis and cancer chemotherapy. Philos Trans R Soc Lond B Biol Sci 1994;345:319-25.
41. Oleinick NL, Agarwal ML, Berger NA, Berger S, Cheng MF, Chatterjee S, et al. Signal transduction and metabolic changes during tumor apoptosis following phthalocyanine-sensitized photodynamic therapy. Proc SPIE 1993;1881:252-61.
42. Slater AF, Stefan C, Nobel I, van den Dobbelsteen DJ, Orrenius S. Signalling mechanisms and oxidative stress in apoptosis. Toxicol Lett 1995;82-83:149-53.
43. Boutin J. Tyrosine protein kinase inhibition and cancer. Int J Biochem 1994;26:1203-26.
44. Gjertsen BT, Doskeland SO. Protein phosphorylation in apoptosis. Biochim Biophys Acta 1995;1269:187-99.
45. Agarwal ML, Larkin HE, Zaidi SI, Mukhtar H, Oleinick NL. Phospholipase activation triggers apoptosis in photosensitized mouse lymphoma. Cancer Res 1993;53:5897-902.
46. Xue LY, He J, Oleinick NL. Rapid tyrosine phosphorylation of HS1 in the response of mouse lymphoma L5178Y-R cells to photodynamic treatment sensitized by the phthalocyanine Pc 4. Photochem Photobiol 1997;66: 105-13.
47. Granville DJ, Levy JG, Hunt DWC. Photodynamic treatment with benzoporphyrin derivative monoacid ring A produces protein tyrosine phosphorylation events and DNA fragmentation in murine P815 cells. Photochem Photobiol 1998;67:358-62.
48. Luo Y, Kessel D. The phosphatase inhibitor calyculin antagonizes the rapid initiation of apoptosis by photodynamic therapy. Biochem Biophys Res Commun 1996;221:72-6.
49. Kessel D, Luo Y, Deng Y, Chang CK. The role of subcellular localization in initiation of apoptosis by photodynamic therapy. Photochem Photobiol 1997;65:422-6.
50. Luo Y, Chang CK, Kessel D. Rapid initiation of apoptosis by photodynamic therapy, Photochem Photobiol 1996;63:528-34.
51. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996;86:147-57.
52. Kluck RM, Martin SJ, Hoffman BM, Zhou JS, Green DR, Newmeyer DD. Cytochrome c activation of CPP32-like proteolysis plays a critical role in a Xenopus cell-free apoptosis system. EMBO J 1997;16:4639-49.
53. Marchetti P, Hirsch T, Zamzami N, Castedo M, Decaudin D, Susin SA, et al. Mitochondrial permeability transition triggers lymphocyte apoptosis. J Immunol 1996;157:4830-6.
54. Zamzami N, Marchetti P, Castedo M, Hirsch T, Susin SA, Masse B, et al. Inhibitors of permeability transition interfere with the disruption of the mitochondrial transmembrane potential during apoptosis. FEBS Lett 1996;384:53-7.
55. Susin SA, Zamzami N, Castedo M, Hirsch T, Marchetti P, Macho A, et al. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J Exp Med 1996;184:1331-41.
56. Kantrow SP, Piantadosi CA. Release of cytochrome c from liver mitochondria during permeability transition. Biochem Biophys Res Commun 1997;232:669-71.
57. Kessel D, Luo Y, Woodburn K, Chang CK, Henderson BW. Mechanisms of phototoxicity catalyzed by two porphycenes. Proc SPIE 1995;2392: 122-8.
58. Gomer CJ, Luna M, Ferrario A, Wong S, Fisher A, Rucker N. Cellular targets and molecular responses associated with photodynamic therapy. J Clin Laser Med Surg 1996;14:315-21.
59. Luna MC, Wong S, Gomer CJ. Photodynamic therapy mediated induction of early response genes. Cancer Res 1994;53:1374-80.
60. Tao J, Sanghera JS, Pelech SL, Wong G, Levy JG. Stimulation of stress-activated protein kinase and p38 HOG1 kinase in murine keratinocytes following photodynamic therapy with benzoporphyrin derivative. J Biol Chem 1996;271:27107-15.
61. Gomer CJ, Luna M, Ferrario A, Rucker N. Increased transcription and translation of heme oxygenase in Chinese hamster fibroblasts following photodynamic stress or Photofrin II incubation. Photochem Photobiol 1991;53:275-9.
62. Gomer CJ, Ferrario A, Rucker N, Wong S, Lee AS. Glucose regulated protein induction and cellular resistance to oxidative stress mediated by porphyrin photosensitization. Cancer Res 1991;51:6574-9.
63. Xue LY, Agarwal ML, Varnes ME. Elevation of GRP-78 and loss of HSP-70 following photodynamic therapy treatment of V79 cells: sensitization by nigericin. Photochem Photobiol 1995;62:135-43.
64. Curry PM, Levy JG. Stress protein expression in murine tumor cells following photodynamic therapy with benzoporphyrin derivative. Photochem Photobiol 1993;58:374-9.
65. Gomer CJ, Ryter SW, Ferrario A, Rucker N, Wong S, Fisher AM. Photodynamic therapy-mediated oxidative stress can induce expression of heat shock proteins. Cancer Res 1996;56:2355-60.
66. He J, Agarwal ML, Larkin HE, Friedman LR, Xue LY, Oleinick NL. The induction of partial resistance to photodynamic therapy by the protooncogene BCL-2. Photochem Photobiol 1996;64:845-52.
67. Fisher AM, Danenberg K, Banerjee D, Bertino JR, Danenberg P, Gomer CJ. Increased photosensitivity in HL60 cells expressing wild-type p53. Photochem Photobiol 1997;66:265-70.
68. Fisher AM, Rucker N, Wong S, Gomer CJ. Differential photosensitivity in wild-type and mutant p53 human colon carcinoma cell lines. J Photochem Photobiol 1998;42:104-7.
69. Luna MC, Ferrario A, Rucker N, Gomer CJ. Decreased expression and function of alpha-2 macroglobulin receptor/low density lipoprotein receptor-related protein in photodynamic therapy-resistant mouse tumor cells. Cancer Res 1995;55:1820-3.
70. Gollnick SO, Liu X, Owczarczak B, Musser DA, Henderson BW. Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic therapy in vivo. Cancer Res 1997;57:3904-9.
71. Kick G, Messer G, Goetz A, Plewig G, Kind P. Photodynamic therapy induces expression of interleukin 6 by activation of AP-1 but not NF-kappa B DNA binding. Cancer Res 1995;55:2373-9.
72. Ryter SW, Gomer CJ. Nuclear factor kappa B binding activity in mouse L1210 cells following photofrin II-mediated photosensitization. Photochem Photobiol 1993;58:753-6.
73. Musser DA, Wagner JM, Weber FJ, Datta-Gupta N. The binding of tumor localizing porphyrins to a fibrin matrix and their effects following photoirradiation, Res Commun Chem Pathol Pharmacol 1980;28:505-25.
74. Dvorak HF, Dvorak AM, Manseau EJ, Wilberg L, Churchill WH. Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression. J Natl Cancer Inst 1979;62:1459-72.
75. Dvorak HF, Orenstein NS, Carvalho AC, Churchill WH, Dvorak AM, Galli SJ, et al. Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J Immunol 1979;122:166-74.
76. Freitas I. Lipid accumulation: the common feature to photosensitizer-retaining normal and malignant tissues. J Photochem Photobiol B 1990; 7:359-61.
77. Kessel D. HPD: structure and determinants of localization. In: Kessel D, editor. Photodynamic therapy of neoplastic diseases. Boca Raton: CRC Press, 1990:1-14.
78. Berg K, Anholt H, Moan J, Ronnestad A, Rimington C. Photobiological properties of haematoporphyrin diesters: evaluation of possible applications in photochemotherapy. J Photochem Photobiol B 1995;20:37-45.
79. Ricchelli F, Gobbo S, Jori G, Moreno G, Vinzens F, Salet C. Photosensitization of mitochondria by liposome-bound porphyrins. Photochem Photobiol 1993;58:53-8.
80. Jori G, Reddi E, Cozzani I, Tomio L. Controlled targeting of different subcellular sites by porphyrins in tumor-bearing mice. Br J Cancer 1986; 53:615-21.
81. Jori G. Tumour photosensitizers: approaches to enhance the selectivity and efficiency of photodynamic therapy. J Photochem Photobiol B 1996; 36:87-93.
82. Soncin M, Polo L, Reddi E, Jori G, Kenney ME, Cheng G, et al. Effect of axial ligation and delivery system on the tumor-localising and -photosensitising properties of Ge(IV)-octabutoxy-phthalocyanines. Br J Cancer 1995;71:727-32.
83. Jori G, Reddi E. The role of lipoproteins in the delivery of tumor-targeting photosensitizers. Int J Biochem 1993;25:1369-75.
84. Polo L, Bianco G, Reddi E, Jori G. The effect of different liposomal formulations on the interaction of Zn (II)-phthalocyanine with isolated low and high density lipoproteins. Int J Biochem Cell Biol 1995;27: 1249-55.
85. Allison BA, Pritchard PH, Richter AM, Levy JG. The plasma distribution of benzoporphyrin derivative and the effects of plasma lipoproteins on its biodistribution. Photochem Photobiol 1990;52:501-7.
86. Allison BA, Waterfield E, Richter AM, Levy JG. The effects of plasma lipoproteins on in vitro tumor cell killing and in vivo tumor photosensitization with benzoporphyrin derivative. Photochem Photobiol 1991;54: 709-15.
87. Allison BA, Pritchard PH, Levy JG. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. Br J Cancer 1994; 69:833-9.
88. Kongshaug M. Distribution of tetrapyrrole photosensitizers among human plasma proteins. Int J Biochem 1992;24:1239-65.
89. Korbelik M. Low density lipoprotein receptor pathway in the delivery of Photofrin: how much is it relevant for selective accumulation of the photosensitizer in tumors? J Photochem Photobiol B 1992;12:107-19.
90. Kongshaug M. Ph. D. thesis. The University of Oslo, Oslo, 1993.
91. Mew D, Wat CK, Towers GHN, Levy JG. Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-porphyrin conjugates. J Immunol 1993;130:1473-7.
92. Hasan T. Photosensitizer delivery mediated by macromolecular carrier systems. In: Henderson BW, Dougherty TJ, editors. Photodynamic Therapy. Basic Principles and Clinical Applications. New York: Marcel-Dekker, 1992: 187-200.
93. Bugelski PJ, Porter CW, Dougherty TJ. Autoradiographic distribution of hematoporphyrin derivative in normal and tumor tissue of the mouse. Cancer Res 1981;41:4604-12.
94. Korbelik M, Krosol G, Chaplin DJ. Photofrin uptake by murine macrophages. Cancer Res 1991;51:2251-5.
95. Korbelik M, Krosol G, Olive PL, Chaplin DJ. Distribution of Photofrin between tumour cells and tumour associated macrophages. Br J Cancer 1991;64:508-12.
96. Eden M, Haines B, Kahler H. The pH of rat tumors measured in vivo. J Natl Cancer Inst 1955;16:541-56.
97. Gullino PM, Clark SH, Grantham FH. The interstitial fluid of solid tumors. Cancer Res 1964;24:780-97.
98. Gullino PM, Grantham FH, Smith SH, Haggerty AC. Modifications of the acid-base status of the internal milieu of tumors. J Natl Cancer Inst 1965; 34:857-69.
99. Thistlethwaite AJ, Leeper DB, Moylan DJ 3rd, Nerlinger RE. pH distribution in human tumors. Int J Radiat Oncol Biol Phys 1985;11:1647-52.
100. 2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 1997;3:177-82.
101. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989;49:4373-84.
102. Gerweck LE, Seetharaman K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res 1996;56:1194-8.
103. Dickson JA, Calderwood SK. Effects of hyperglycemia and hyperthermia on the pH, glycolysis and respiration of the Yoshida sarcoma in vivo. J Natl Cancer Inst 1979;63:1371-81.
104. Barrett AJ, Kennedy JC, Jones RA, Nadeau P, Pottier RH. The effect of tissue and cellular pH on the selective biodistribution of porphyrin-type photochemotherapeutic agents: a volumetric titration study. J Photochem Photobiol B 1990;6:309-23.
105. Pottier R, Kennedy JC. The possible role of ionic species in selective biodistribution of photochemotherapeutic agents toward neoplastic tissue. J Photochem Photobiol B 1990;8:1-16.
106. Moan J, Smedshammer L, Christensen T. Photodynamic effects on human cells exposed to light in the presence of hematoporphyrin. pH effects. Cancer Lett 1980;9:327-32.
107. Bohmer RM, Morstyn G. Uptake of hematoporphyrin derivative by normal and malignant cells: effect of serum, pH, temperature, and cell size. Cancer Res 1985;45:5328-34.
108. Thomas JP, Girotti AW. Glucose administration augments in vivo uptake and phototoxicity of the tumor-localizing fraction of hematoporphyrin derivative. Photochem Photobiol 1989;49:241-7.
109. Peng Q, Moan J, Cheng LS. The effect of glucose administration on the uptake of photofrin II in a human tumor xenograft. Cancer Lett 1991;58: 29-35.
110. Henderson BW, Waldow SM, Mang TS, Potter WR, Malone PB, Dougherty TJ. Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. Cancer Res 1985;45:572-6.
111. Henderson BW, Sumlin AB, Owczarczak BL. Dougherty TJ. Bacteriochlorophyll-a as photosensitizer for photodynamic treatment of transplantable murine tumors. J Photochem Photobiol B 1991;10:303-13.
112. Henderson BW, Vaughan L, Bellnier DA, van Leengoed H, Johnson PG, Oseroff AR. Photosensitization of murine tumor, vasculature and skin by 5-aminolevulinic acid-induced porphyrin. Photochem Photobiol 1995;62: 780-9.
113. Cincotta L, Foley JW, MacEachern T, Lampros E, Cincotta AH. Novel photodynamic effects of a benzophenothiazine on two different murine sarcomas. Cancer Res 1994;54:1249-58.
114. Chan WS, Brasseur N, La Madeleine C, van Lier JE. Evidence for different mechanisms of EMT-6 tumor necrosis by photodynamic therapy with disulfonated aluminum phthalocyanine or photofrin: tumor cell survival and blood flow. Anticancer Res 1996;16:1887-92.
115. Sitnik TM, Henderson BW. Effects of fluence rate on cytotoxicity during photodynamic therapy. Proc SPIE 2972. In press.
116. Mayhew E, Vaughan L, Panus A, Murray M, Henderson BW. Lipid-associated methylpheophorbide-a (hexyl-ether) as a photodynamic agent in tumor-bearing mice. Photochem Photobiol 1993;58:845-51.
117. Korbelik M, Krosl G. Cellular levels of photosensitisers in tumors: the role of proximity to the blood supply. Br J Cancer 1994;70:604-10.
118. Tromberg BJ, Orenstein A, Kimel S, Barker SJ, Hyatt J, Nelson JS, et al. In vivo tumor oxygen tension measurements for the evaluation of the efficiency of photodynamic therapy. Photochem Photobiol 1990;52: 375-85.
119. Zilberstein J, Bromberg A, Frantz A, Rosenbach-Belkin V, Kritzman A, Pfefermann R, et al. Light-dependent oxygen consumption in bacterio-chlorophyll-serine-treated melanoma tumors: on-line determination using a tissue-inserted oxygen microsensor. Photochem Photobiol 1997;65: 1012-9.
120. Foster TH, Murant RS, Bryant RG, Knox RS, Gibson SL, Hilf R. Oxygen consumption and diffusion effects in photodynamic therapy. Radiat Res 1991;126:296-303.
121. Nichols MG, Foster TH. Oxygen diffusion and reaction kinetics in the photodynamic therapy of multicell tumor speroids. Phys Med Biol 1994; 39:2161-81.
122. Georgakoudi I, Nichols MG, Foster TH. The mechanism of Photofrin photobleaching and its consequences for photodynamic dosimetry. Photochem Photobiol 1997;65:135-44.
123. Gibson SL, VanDerMeid KR, Murant RS, Raubertas RF, Hilf R. Effects of various photoradiation regimens on the antitumor efficacy of photodynamic therapy for R3230AC mammary carcinomas. Cancer Res 1990;50: 7236-41.
124. Blant SA, Woodtli A, Wagnieres G, Fontolliet C, van den Bergh H, Monnier P. In vivo fluence rate effect in photodynamic therapy of early cancers with tetra(m-hydroxyphenyl)chlorin. Photochem Photobiol 1996; 64:963-8.
125. Iinuma S, Wagnieres G, Schomacker KT, Bamberg M, Hasan T. The importance of fluence rate in photodynamic therapy with ALA-induced PpIX and BPD-MA in a rat bladder tumor model. In: Dougherty TJ, editor. Optical methods for tumor treatment and detection: mechanisms and techniques in photodynamic therapy IV. SPIE Press: Bellingham, WA, 1995:136-40.
126. van Geel IP, Oppelaar H, Marijnissen JP, Stewart FA. Influence of fractionation and fluence rate in photodynamic therapy with Photofrin or mTHPC. Radiat Res 1996;145:602-9.
127. Henderson BW, Fingar VH. Oxygen limitation of direct tumor cell kill during photodynamic treatment of a murine tumor model. Photochem Photobiol 1989;49:299-304.
128. Star WM, Marijnissen HP, van den Berg-Blok AE, Versteeg JA, Franken KA, Reinhold HS. Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. Cancer Res 1986;46: 2532-40.
129. Nelson JS, Liaw LH, Orenstein A, Roberts WG, Berns MW. Mechanism of tumor destruction following photodynamic therapy with hematoporphyrin derivative, chlorin, and phthalocyanine. J Natl Cancer Inst 1988; 80:1599-605.
130. Roberts DJH, Cairnduff F, Driver I, Dixon B, Brown SB. Tumour vascular shutdown following photodynamic therapy based on polyhaematoporphyrin or 5-aminolaevulinic acid. Int J Oncol 1994;5:763-8.
131. Henderson BW, Fingar VH. Relationship of tumor hypoxia and response to photodynamic treatment in an experimental mouse tumor. Cancer Res 1987;47:3110-4.
132. Chen Q, Chen H, Hetzel FW. Tumor oxygenation changes post-photodynamic therapy. Photochem Photobiol 1996;63:128-31.
133. Fingar VH, Siegel KA, Wieman TJ, Doak KW. The effects of thromboxane inhibitors on the microvascular and tumor response to photodynamic therapy. Photochem Photobiol 1993;58:393-9.
134. Fingar VH, Wieman TJ, Haydon PS. The effects of thrombocytopenia on vessel stasis and macromolecular leakage after photodynamic therapy using photofrin. Photochem Photobiol 1997;66:513-7.
135. Fingar VH, Wieman TJ, Karavolos PS, Doak KW, Quellet R, van Lier JE. The effects of photodynamic therapy using differently substituted zinc phthalocyanines on vessel constriction, vessel leakage and tumor response. Photochem Photobiol 1993;58:251-8.
136. 6 on vessel constriction, vessel leakage, and tumor response. Cancer Res 1994;54:5374-9.
137. Gilissen MJ, van de Merbel-de Wit LE, Star WM, Koster JF, Sluiter W. Effect of photodynamic therapy on the endothelium-dependent relaxation of isolated rat aortas. Cancer Res 1993;53:2548-52.
138. Fingar VH, Wieman TJ, Doak KW. Role of thromboxane and prostacyclin release on photodynamic therapy-induced tumor destruction. Cancer Res 1990;50:2599-603.
139. Stern SJ, Craig JR, Flock S, Small S. Effect of aspirin on photodynamic therapy utilizing chloroaluminum sulfonated phthalocyanine (CASP). Lasers Surg Med 1992;12:494-9.
140. Taber SW, Wieman TJ, Fingar VH. The effects of aspirin on microvasculature after photodynamic therapy. Photochem Photobiol 1993;57: 856-61.
141. Korbelik M. The role of nitric oxide in the response of solid tumors to photodynamic therapy. Abstract. Photochem Photobiol 1997;65:55S-56S.
142. Fingar VH, Henderson BW. Drug and light dose dependence of photodynamic therapy: a study of tumor and normal tissue response. Photochem Photobiol 1987;46:837-41.
143. Sitnik TM, Hampton JA, Henderson BW. Reduction of tumor oxygenation during and after photodynamic therapy in vivo: Effects of fluence rate. Br J Cancer 1998;77:1386-94.
144. Reed MW, Wieman TJ, Schuschke DA, Tseng MT, Miller FN. A comparison of the effects of photodynamic therapy on normal and tumor blood vessels in the rat microcirculation. Radiat Res 1989;119:542-52.
145. Korbelik M. Induction of tumor immunity by photodynamic therapy. J Clin Laser Med Surg 1996;14:329-34.
146. Cuenco GM, Knisely TL, Averboukh L, Garett L, Castro S, Cincotta AH. Induction of glucose regulatory proteins in tumor cells after treatment with a benzophenothiazine analogue. Photochem Photobiol 1997;65:19S.
147. Ochsner M. Photophysical and photobiological processes in the photodynamic therapy of tumors. J Photochem Photobiol B 1997;39:1-18.
148. Fingar VH. Vascular effects of photodynamic therapy. J Clin Laser Med Surg 1996;14:323-8.
149. Korbelik M. Photosensitizer distribution and photosensitized damage of tumor tissues. In: Hönigsmann H, Jori G, Young AR, editors. The fundamental bases of phototherapy. Milan: OEMF spa, 1996:229-45.
150. de Vree WJ, Essers MC, Koster JF, Sluiter W. Role of interleukin 1 and granulocyte colony-stimulating factor in photofrin-based photodynamic therapy of rat rhabdomyosarcoma tumors. Cancer Res 1997;57:2555-8.
151. Nseyo UO, Whalen RK, Duncan MR, Berman B, Lundahl SL. Urinary cytokines following photodynamic therapy for bladder cancer. A preliminary report. Urology 1990;36:167-71.
152. Evans S, Matthews W, Perry R, Fraker D, Norton J, Pass HI. Effect of photodynamic therapy on tumor necrosis factor production by murine macrophages. J Natl Cancer Inst 1990;82:34-9.
153. Canti G, Franco P, Marelli O, Ricci L, Nicolin A. Hematoporphyrin derivative rescue from toxicity caused by chemotherapy or radiation in a murine leukemia model (L1210). Cancer Res 1984;44:1551-6.
154. Hunt DW, Sorrenti RA, Smits CB, Levy JG. Photofrin, but not benzoporphyrin derivative, stimulates hematopoiesis in the mouse. Immunopharmacology 1993;26:203-12.
155. Krosl G, Korbelik M, Dougherty GJ. Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy. Br J Cancer 1995;71:549-55.
156. Gallin JI. Inflammation. In: Paul WE, editor. Fundamental immunology. New York: Raven Press, 1989:721-33.
157. de Vree WJ, Essers MC, de Bruijn HS, Star WM, Koster JF, Sluiter W. Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo. Cancer Res 1996;56:2908-11.
158. Krosl G, Korbelik M, Krosl J, Dougherty GJ. Potentiation of photodynamic therapy-elicited antitumor response by localized treatment with granulocyte-macrophage colony-stimulating factor. Cancer Res 1996;56: 3281-6.
159. Yamamoto N, Hoober JK, Yamamoto N, Yamamoto S. Tumoricidal capacities of macrophages photodynamically activated with hematoporphyrin derivative. Photochem Photobiol 1992;56:245-50.
160. Qin B, Selman SH, Payne KM, Keck RW, Metzger DW. Enhanced skin allograft survival after photodynamic therapy. Association with lymphocyte inactivation and macrophage stimulation. Transplantation 1993;56: 1481-6.
161. Korbelik M, Krosl G. Enhanced macrophage cytotoxicity against tumor cells treated with photodynamic therapy. Photochem Photobiol 1994;60: 497-502.
162. Korbelik M, Naraparaju VR, Yamamoto N. Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer. Br J Cancer 1997;75:202-7.
163. Canti G, Lattuada D, Nicolin A, Taroni P, Valentini G, Cubeddu G. Antitumor immunity induced by photodynamic therapy with aluminum phthalocyanine and laser light. Anticancer Drugs 1994;5:443-7.
164. Korbelik M, Krosl G, Krosl J, Dougherty GJ. The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. Cancer Res 1996;56:5647-52.
165. Hendrzak-Henion JA, Knisely TL, Cincotta E, Castro S, Garrett L, Cincotta AH. Induction of systemic antitumor immunity by benzophenothiazine photodynamic therapy. Phtotchem Photobiol 1997;65:19S.
166. Lynch DH, Haddad S, King VJ, Ott MJ, Straight RC, Jolles CJ. Systemic immunosuppression induced by photodynamic therapy (PDT) is adoptively transferred by macrophages. Photochem Photobiol 1989;49: 453-8.
167. Obochi MO, Ratkay LG, Levy JG. Prolonged skin allograft survival after photodynamic therapy associated with modification of donor skin antigenicity. Transplantation 1997;63:810-7.
168. Lightdale CJ, Heier SK, Marcon NE, McCoughan JS Jr., Gerdes H, Overholt BF, et al. Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Gastrointest Endosc 1995;42:507-12.
169. Dugan M, Crawford E, Nseyo U. Photodynamic therapy (PDT) after transurethal resection (tur) for superficial papillary bladder carcinoma (SBC): a randomized trial. Proc ASCO 1991;10:173.
170. Nseyo U, Dehaven J, Dougherty T. Photodynamic therapy (PDT) in the management of patients with resistant superficial bladder cancer: a long term experience. J Clin Laser Med Surg 1998;16:61-8.
171. Lam S, Crofton C, Cory P. Combined Photodynamic Therapy (PDT) using Photofrin and radiotherapy (XRT) versus radiotherapy alone in patients with inoperable distribution non-small cell bronchogenic cancer. Proc SPIE Proc 1991;20-28.
172. Nagamoto N, Saito Y, Ohta S, Sato M, Kanma K, Sagawa M, et al. Relation of lymphnode metastasis to primary tumor size and microscopic appearance of roentgenographically occult lung cancer. Am J Surg Pathol 1989;13:1009-13.
173. Edell ES, Cortese DA. Photodynamic therapy in the management of early superficial squamous cell carcinoma as an alternative to surgical resection. Chest 1992;102:1319-22.
174. Furuse K, Fukuoka M, Kato H, Horai T, Kubota K, Kodama N, et al. Prospective phase II study on photodynamic therapy with photofrin ii for centrally located early-stage lung cancer. The Japan Lung Center. J Clin Oncol 1993;11:1852-7.
175. Kato H, Okunaka T, Shimatani H. Photodynamic therapy for early stage bronogenic carcinoma. J Clin Laser Med Surg 1996;14:235-8.
176. Overholt BF, Panjehpour M. Photodynamic therapy for Barrett's esophagus. Gastrointest Endosc Clin N Am 1997;7:207-20.
177. Biel M. Photodynamic therapy and the treating of head and neck cancers. J Clin Laser Radiat Surg 1996;14:239-44.
178. Nseyo UO. Photodynamic therapy. Urol Clin North Am 1992;19:591-9.
179. Muller PJ, Wilson BC. Photodynamic therapy for recurrent supratentorial gliomas. Semin Surg Oncol 1995;11:346-54.
180. Papovic E, Kaye A, Hill J. Photodynamic therapy of brain tumors. J Clin Laser Radiat Surg 1996;14:251-62.
181. Tochner AZ, Pass HI, Smith PD, DeLaney TF, Sprague M, DeLuca AM, et al. Intrathoracic photodynamic therapy: a canine normal tissue tolerance study and early clinical experience. Lasers Surg Med 1994;14:118-23.
182. Pass H, Donington J. Photodynamic therapy for the management of pleural malignancies. Sem Surg Oncol 1995;11:360-7.
183. Takita H, Dougherty TJ. Intracavitary photodynamic therapy for malignant pleural mesothelioma. Semin Surg Oncol 1995;11:368-71.
184. DeLaney TF, Sindelar WF, Tochner Z, Smith PD, Friauf WS, Thomas G, et al. Phase I study of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Int J Radiat Oncol Biol Phys 1993; 25:445-57.
185. Razum N, Snyder A, Doiron D. SnET2: Clinical update. Proc SPIE 1996; 2675:43-6.
186. Renschler M, Yuen A, Panella T. Photodynamic therapy trials with Lutetium Texaphyrin. Photochem Photobiol 1997;65:475 (Abstract).
187. Leung J. Photosensitizers in photodynamic therapy. Semin Oncol 1994; 21:4-10.
188. Gragoudas E, Schmidt-Erfurth U, Sickenkey M. Results and preliminary dosimetry of photodynamic therapy for choroidal neovascularization in age-related macular degeneration in a phase I/II study. Abstract. Assoc Res Vision Opthamology 1997;38:73.
189. Schmidt-Erfurth U, Miller J, Sickenkey M. Photodynamic therapy for choroidal neovascularization in a phase II study. Preliminary results of multiple treatments. Assoc Res Vision Opthamology 1997;38:74 (Abstract).
190. Berenbaum M, Bonnett R, Cheorettan E. Selectivity of meso-tetra-(hydroxyphenyl) porphyrins and chlorins and photofrin in causing photodamage in tumor, skin, muscle and bladder. Laser Med Sci 1993;8: 235-43.
191. Grosjean P, Savary J, Wagnieres G. Tetra(m-hydroxyphenyl) chlorin clinical photodynamic therapy of early bronchial and oseophageal cancers. Laser Med Sci 1993;8:235-43.
192. Dilkes MG, De Jode ML, Rowntree-Taylor A. m-THPC photodynamic therapy for head and neck cancer. Lasers Med Sci 1997;11:23-30.
193. Allen RP, Kessel D, Tharratt RS, Volz W. Photodynamic therapy of superficial malignancies with NPe6 in man. In: Spinelli P, Dal Fante M, Marchesini R, editors. Photodynamic therapy and biomedical lasers. Amsterdam: Elsevier Science Publishers BV, 1992:441-5.
194. Malik Z, Lugaci H. Destruction of erythroleukaemic cells by photoactivation of endogenous porphyrins. Br J Cancer 1987;56:589-95.
195. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 1990;6:143-8.
196. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinical useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 1992;14:275-92.
197. Peng Q, Berg K, Moan J, Kongshaug M, Nesland JM. 5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem Photobiol 1997;65:235-51.
198. Kennedy JC, Marcus SL, Pottier RH. Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): mechanisms and clinical results. J Clin Laser Med Surg 1996;14:289-304.
199. Peng Q, Warloe T, Berg K, Moan J, Kongshaug M, Giercksky KE, et al. 5-Aminolevulinic acid-based photodynamic therapy: clinical research and future challenges. Cancer 1997;79:2282-308.
200. Webber J, Kessel D, Fromm D. Side effects and photosensitization of human tissues after aminolevulinic acid. J Surg Res 1997;68:31-7.
201. Fan KF, Hopper C, Speight PM, Buonaccorsi G, MacRobert AJ, Bown SG. Photodynamic therapy using 5-aminolevulinic acid for premalignant and malignant lesions of the oral cavity. Cancer 1996;78:1374-83.
202. Barr H, Shepherd NA, Dix A, Roberts DJ, Tan WC, Krasner N. Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 1996;348:584-5.
203. Bown SG, Millson CE. Photodynamic therapy in gastroenterology. Gut 1997;41:5-7.
204. Kriegmair M, Baumgartner R, Knuechel R, Steinbach P, Ehsan A, Lumper W, et al. Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology 1994;44:836-41.
205. Kriegmair M, Baumgartner R, Knuchel R, Stepp H, Hofstadter F, Hofstetter A. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol 1996;155:105-10.
206. Marcus SL. Clinical photodynamic therapy: the continuing evolution. In: Henderson BW, Dougherty TJ, editors. Photodynamic therapy. New York: Marcel Dekker Inc., 1992:219-68.
207. Ris HB, Altermatt HJ, Nachbur B, Stewart JC, Wang Q, Lim CK, et al. Effect of drug-light interval on photodynamic therapy with meta-tetrahydroxyphenylchlorin in malignant mesothelioma. Int J Cancer 1993; 53:141-6.
208. Svaasand LO. Photodynamic and photohyperthermia response of malignant tumors. Med Phys 1985;12:455-61.
209. Henderson BW, Waldow SM, Potter WR, Dougherty TJ. Interaction of photodynamic therapy and hyperthermia: tumor response and cell survival studies after treatment of mice in vivo. Cancer Res 1985;45:6071-7.
210. Levendag PC, Marijnissen HP, de Ru VJ, Versteeg JA, van Rhoon GC, Star WM. Interaction of interstitial photodynamic therapy and interstitial hyperthermia in a rat rhabdomyosarcoma - a pilot study. Int J Radiat Oncol Biol Phys 1988;14:139-45.
211. Leunig M, Leunig A, Lankes P, Goetz AE. Evaluation of photodynamic therapy-induced heating of hamster melanoma and its effect on local tumor eradication. Int J Hyperthermia 1994;10:297-306.
212. Marijnissen JPA, Baas P, Beek JF, van Moll JH, van Zandwijk N, Star WM. Pilot study on light dosimetry for endobronchial photodynamic therapy. Photochem Photobiol 1993;58:92-9.
213. Rasch MH, Tijssen Karmi, VanSteveninck J, Dubbelman TM. Synergistic interaction of photodynamic treatment with the sensitizer aluminum phthalocyanine and hyperthermia on loss of clonogenicity of CHO cells. Photochem Photobiol 1996;64:586-93.
214. Chen Q, Chen H, Shapiro H, Hetzel FW. Sequencing of combined hyperthermia and photodynamic therapy. Radiat Res 1996;146:293-7.
215. De Jode ML, Mcgilligan JA, Dilkes MG, Cameron I, Hart PB, Grahn MF. A comparison of novel light sources for photodynamic therapy. Lasers Med Sci 1997;12:260-8.
216. Whitehurst C, Byrne K, Moore JV. Development of an alternative light source to lasers for photodynamic therapy:1. comparative in vitro dose response characteristics. Lasers Med Sci 1993:8259-67.
217. Ripley PM. The physics of diode lasers. Lasers Med Sci 1996;11:71-8.
218. Yariv A. Quantum electronics. Chapter 17. New York: John Wiley & Sons, 1989.
219. Zhou JX, Hou X, Tsai SJ, Yang KX, Michel RG. Characterization of a tunable optical parametric oscillator laser system for multielement flame laser excited atomic fluorescence spectrometry of cobalt, copper, lead, manganese, and thallium in buffalo river sediment. Anal Chem 1997;69: 490-9.
220. Hizazumi H, Naito K, Misakii T, Koshida K, Yamamoto H. An experimental study of photodynamic therapy using a pulsed gold vapour laser. In: Jori G, editor. Photodynamic therapy of tumors and other diseases. Padova, Italy: Edizioni Libreria Progetto, 1985:251-4.
221. Moan J, Iani V, Ma LW. Choice of the proper wavelength for photochemotherapy. In: Ehrenberg B, Jori G, Moan J, editors. Photochemotherapy photodynamic therapy and other modalities. Proc SPIE 1996;2625: 544-9.